dna-hiv-pt123

Vaccineexperimental

Clinical trial activity

10 trials · 26 clinical orgs · 0 marketing orgs

Phase 1
9
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Aug 1, 2012 (NCT01799954)

Timeline

2010s

  1. Jan 1, 2012

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • dna-hiv-pt123

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04844775Phase 1Jun 30, 2021CHU Henri Mondor, European Commission, EuroVacc Foundation, Government of France, Government of Switzerland, Imperial College London, Medical Research Council, University of London
NCT04066881Phase 2Jan 31, 2020CONRAD, EuroVacc Foundation, Gilead Sciences, Government of Mozambique, Imperial College London, International AIDS Vaccine Initiative, Karolinska Institute, Ludwig Maximilians University, Medical Research Council, Medical Research Council, South Africa, Medical Research Council-UVRI Uganda Research Unit on AIDS, Muhimbili University, National Institute for Medical Research, Tanzania, University of Lausanne, University of London
NCT03391375Phase 1Mar 15, 2017EuroVacc Foundation, International AIDS Vaccine Initiative, Medical Research Council-UVRI Uganda Research Unit on AIDS, University of Lausanne
NCT02915016Phase 1/Phase 2 (Phase 2)Dec 1, 2016Centre for the AIDS Programme of Research in South Africa, National Institute of Allergy and Infectious Diseases (NIAID)
NCT02997969Phase 1May 1, 2016HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), Novartis, University of Lausanne, University of North Carolina at Chapel Hill
NCT02207920Phase 1Jul 1, 2014National Institute of Allergy and Infectious Diseases (NIAID), University of Rochester
NCT01964937Phase 1Oct 15, 2013EuroVacc Foundation, National Institute of Allergy and Infectious Diseases (NIAID), University of Lausanne, University of Rochester
NCT01927835Phase 1Aug 20, 2013Columbia University, EuroVacc Foundation, HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), University of Lausanne
NCT01783977Phase 1Apr 1, 2013National Institute of Allergy and Infectious Diseases (NIAID), University of Lausanne
NCT01799954Phase 1Aug 1, 2012HIV Vaccine Trials Network, University of Lausanne
Showing 10 of 10 trials
Page 1 / 1

Organizations

Research & Development (26)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of LausanneAcademic/Hospital7022012
National Institute of Allergy and Infectious Diseases (NIAID)Government6622013
EuroVacc FoundationAcademic/Hospital5122013
HIV Vaccine Trials NetworkAcademic/Hospital3112012
Imperial College LondonAcademic/Hospital2022020
International AIDS Vaccine InitiativeAcademic/Hospital2022017
Medical Research CouncilGovernment2022020
Medical Research Council-UVRI Uganda Research Unit on AIDSAcademic/Hospital2122017
University of LondonAcademic/Hospital2022020
University of RochesterAcademic/Hospital2012013
Centre for the AIDS Programme of Research in South AfricaGovernment1012016
CHU Henri MondorAcademic/Hospital1012021
Columbia UniversityAcademic/Hospital1012013
CONRADFor profit1012020
European CommissionGovernment1012021
Gilead SciencesFor profit1012020
Government of FranceGovernment1112021
Government of MozambiqueGovernment1012020
Government of SwitzerlandGovernment1012021
Karolinska InstituteAcademic/Hospital1012020
26 organizations
Page 1 / 2